Press coverage about Tandem Diabetes Care (NASDAQ:TNDM) has trended somewhat positive recently, according to Accern Sentiment. Accern identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Tandem Diabetes Care earned a media sentiment score of 0.20 on Accern’s scale. Accern also assigned news coverage about the medical device company an impact score of 45.4576898564752 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

These are some of the media stories that may have effected Accern Sentiment Analysis’s analysis:

A number of brokerages recently weighed in on TNDM. Piper Jaffray Companies reaffirmed a “hold” rating and set a $1.50 price objective on shares of Tandem Diabetes Care in a research report on Friday. Zacks Investment Research raised shares of Tandem Diabetes Care from a “hold” rating to a “buy” rating and set a $0.75 price objective for the company in a research report on Thursday, September 28th. Five investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Tandem Diabetes Care has an average rating of “Buy” and an average target price of $4.09.

Shares of Tandem Diabetes Care (TNDM) opened at 0.82 on Friday. The company’s market cap is $41.19 million. The company’s 50 day moving average is $0.69 and its 200-day moving average is $0.81. Tandem Diabetes Care has a 12 month low of $0.39 and a 12 month high of $8.10.

Tandem Diabetes Care (NASDAQ:TNDM) last released its quarterly earnings data on Thursday, July 27th. The medical device company reported ($0.44) EPS for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.04. Tandem Diabetes Care had a negative net margin of 110.70% and a negative return on equity of 1,177.11%. The company had revenue of $21.30 million during the quarter, compared to the consensus estimate of $21.74 million. During the same period last year, the firm earned ($0.60) EPS. The firm’s revenue for the quarter was down 7.4% compared to the same quarter last year. Analysts expect that Tandem Diabetes Care will post ($1.79) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was first posted by Watch List News and is the property of of Watch List News. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this report can be viewed at

About Tandem Diabetes Care

Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).

Insider Buying and Selling by Quarter for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.